AARDEX Group is dedicated to advancing clinical research and improving patient outcomes through our innovative solutions for measuring and managing medication adherence. We recognize that clinical trials are complex endeavors requiring multiple stakeholders' involvement, each with unique expertise and capabilities. That's why we have built an ecosystem of partners who share our vision and commitment to improving patient outcomes through clinical trial success.
Our ecosystem includes some of the most prominent and respected names in the industry, including CMOs, CROs, EDC, IRT, DCT vendors, and several industry-leading adherence packaging and device developers. By collaborating with these partners, AARDEX Group is leading the way in streamlining the approach to measuring and managing adherence in various clinical trial settings, including site-based, hybrid, and decentralized.
Our partners bring a wealth of knowledge and expertise to the table. By working together, we can develop innovative solutions that address the unique challenges of clinical trial adherence management. Our collective efforts are transforming how medication adherence is measured and managed, resulting in more accurate data and improved patient outcomes.
At AARDEX Group, we are proud to be part of a network of partners that is making a significant impact on the field of clinical research. Our commitment to advancing clinical trial success through collaboration and innovation is unwavering, and we look forward to continuing to work with our partners to improve the lives of patients everywhere.
WEBINAR WITH MERCK & BIOGEN
Mitigating the Risk of Poor Adherence in Trials
Watch this live recording with adherence experts from Merck & Biogen to learn about their approach to mitigating the risk of poor adherence in trials.
FROM THE AARDEX GROUP BLOG
We are thrilled to feature expert insights from Bernard Vrijens, a world-renowned expert on medication adherence. Taking medication as prescribed is crucial to achieving optimal health outcomes, yet non-adherence is a prevalent issue. Bernard Vrijens' extensive research and experience in the field provide invaluable insights into the factors that contribute to medication non-adherence and effective strategies to address them. His contributions to our medication adherence blog offer actionable advice and evidence-based recommendations to improve medication adherence and ultimately, patient outcomes.
Clearly it is in no one’s interests for a clinical trial to fail. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. Beyond the sponsor’s missed commercial opportunity, there are missed opportunities to advance
In a clinical trial, every piece of data contributes to the overall story being told. No matter how small or seemingly insignificant, all the information that emerges over the course of the process adds rich detail to the narrative. Two
AARDEX Group Belgium – SHL Medical, a world-leading provider of drug delivery devices, and AARDEX Group, the global leader in medication adherence solutions, today announced their strategic partnership aimed at delivering an end-to-end solution for pharma customers seeking to demonstrate
It is perhaps ironic that Alexander Graham Bell, often singled out as the individual who invented the telephone, was a man who believed in the value of collective endeavour. Indeed, Bell is quoted as saying: “Great discoveries and improvements invariably
In 1920, The Lancet published a paper authored by T.C. Graves entitled ‘Commentary on a case of hystero-epilepsy with delayed puberty: Treated with testicular extract’. While the article was not the first to mention the placebo effect, it is recognised
Among the many forces that can influence clinical trials, arguably not enough attention is paid to status quo bias. A common phenomenon, status quo bias can explain why any proposed departure from existing expectations or dominant practice can be